Juno Therapeutics Inc - Strategic SWOT Analysis Review

August 2018 | 39 pages | ID: J0CDAD73C1EEN
GlobalData

Abstracts

Juno Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin's Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc Key Recent Developments

Jan 12,2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
Jan 05,2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer
Dec 20,2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
Nov 27,2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Nov 01,2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Juno Therapeutics Inc - Key Facts
Juno Therapeutics Inc - Key Employees
Juno Therapeutics Inc - Key Employee Biographies
Juno Therapeutics Inc - Major Products and Services
Juno Therapeutics Inc - History
Juno Therapeutics Inc - Company Statement
Juno Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Juno Therapeutics Inc - Business Description
R&D Overview
Juno Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Juno Therapeutics Inc - Strengths
Juno Therapeutics Inc - Weaknesses
Juno Therapeutics Inc - Opportunities
Juno Therapeutics Inc - Threats
Juno Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Juno Therapeutics Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO
Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer
Dec 20, 2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results
Oct 12, 2017: Biomarkers May Help Identify Patients at Increased Risk of Neurotoxicity From CD19 CAR T-cell Therapy
Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Juno Therapeutics Inc, Key Facts
Juno Therapeutics Inc, Key Employees
Juno Therapeutics Inc, Key Employee Biographies
Juno Therapeutics Inc, Major Products and Services
Juno Therapeutics Inc, History
Juno Therapeutics Inc, Subsidiaries
Juno Therapeutics Inc, Joint Venture
Juno Therapeutics Inc, Key Competitors
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Juno Therapeutics Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Tragara Pharmaceuticals Inc
Novartis Pharmaceuticals Corp
NeoGenomics Inc
ImmuneXcite Inc
Eiger BioPharmaceuticals Inc